

Good Pharmacovigilance Practices (EU-GVP) - Update

17th Industry Stakeholder Platform – Operation of EU Pharmacovigilance 7 November 2022

Presented by Priya Bahri





Update

- Thanks for comments, interest, participation and adherence from our industry stakeholders
- Plans and priorities for 2023
- Comments on GVP M XVI ADD III
- Multistakeholder drafting group for Reflection Paper on Digital Support to Risk Minimisation Measures and Their Evaluation
- Feedback from industry stakeholders on potential 2024 priorities







- EU-GVP
- Impact research
- PRISMA pilot



EU-GVP Work 2023:

Priority 1: first lane – second lane

- **GVP Module XVI Rev 3 on risk minimisation measures (RMM)**, **Addendum II on RMM evaluation and Addendum III on pregnancy prevention programmes**: Finalisation postpublic consultation, aiming at publication in 2023 (*for ADD III: Review of timetable in June* 2023)
- GVP Chapter P III on pregnancy and breastfeeding: Finalisation of post-consultation, aiming at publication in 2023 (*Review of timetable in June 2023*)
- **GVP Annex I Rev 5 on definitions**: published Rev 4 already includes latest definitions from now applicable clinical trial legislation; previous definitions will be deleted in Rev 5, aiming at publication in 2023
- Reflection Paper on digital support to RMM and their evaluation: Development by multistakeholder drafting group, aiming at public consultation in 2024
 - 3 Priya Bahri: EU-GVP



EU-GVP Work 2023:

Priority 2:

GVP Module VIII Rev 4 on post-authorisation safety studies: started in 2022 (draft scope of revision presented to PRAC Sep 2022) and to be released for public consultation 2023 or 2024 – *Points raised by industry stakeholders?*


Priority 3 :

GVP Module V Rev 3 on risk management system: to be started in 2022/3 and to be released for public consultation (2023 or) 2024 – *Points raised by industry* stakeholders?




GVP Module XVI on risk minimisation measures and Addendum II on effectiveness evaluation

- Public consultation of Module XVI rev 3 and new Addendum II in 2021
- Comments review and finalisation ongoing
- Comments on Module: 697 comments from 27 stakeholder organisations
- Comments on Addendum II: 73 comments (about 2/3 accepted)



EUROPEAN MEDICINES AGENCY






GVP Module XVI Addendum II on RMM effectiveness evaluation - in the final version:

- Improved structure of methods section (qualitative quantitative)
- Emphasis on mixed methods approach
- Reference to human factors/usability engineering techniques
- Clarifications

EUROPEAN MEDICINES AGENCY





Public Consultation in 2022 - 33 commenting parties

- Patient organisations: 3
- Individual patients/citizens: 8 (4 non-EU)
- Healthcare professional organisations: 2
- Learned societies/research consortia at EU or international level: 3
- Learned societies at national level: 1
- Industry organisations at EU level: 3 EFPIA, Medicines for Europe, European CRO Federation
- Industry organisations at national level: 2
- Individual pharmaceutical companies/consultancies: 8 (4 non-EU)
- National competent authorities: 1
- Charity: **1** (non-EU)
- Others: **1**



Public consultation – 369 comments

General comments from public consultation: **90**

Section-specific comments from public consultation

- Introduction: 39
- Criteria: 99
- Figure: 18
- PPP: **122**
- Other: **1**



Public consultation – main themes of comments

- Scope
- Impact of PPP on access to treatment / informed choice concept
- Definitions of criteria and evidence thresholds
- Situations of uncertainty



Multistakeholder Drafting Group for Reflection Paper on Digital Support to Risk Minimisation Measures and Their Evaluation

Patient and consumer representatives: 2

Healthcare professional representatives: **8** presenting the different professions and settings

Industry representatives: **6** (Katharina Bench (Vaccines Europe), Vicky R Edwards (EFPIA), Michael Forstner (Medicines for Europe), Sarah Frise (Vaccines Europe), Randip Kahlon (EFPIA), Klaudija Marijanovic Barac (Medicines for Europe)) – *Names in the public domain?*

EMA Committee representatives: **8** from PRAC (incl. 2 patient and 2 healthcare professional members) and **2** from CMDh

EMA: Priya Bahri, Monica Buch, Sabine Brosch, Machteld van Egmond, Pedro Pina Ferreira, Thomas Goedecke, Viola Macolic-Sarinic, Marie-Helene Pinheiro, Ana Sempere, Elias Tavares, Thorsten Vetter




Status

Reflection Paper on

Digital Support to Risk Minimisation Measures and


Their Effectiveness Evaluation

- Established a multistakeholder drafting group under EU-GVP activities
- Call for themes from stakeholders by 15 August 2022 (input received from EFPIA, Medicines for Europe and Vaccines Europe)
- Meeting on 6 October 2022 to discuss the draft table of contents (to be agreed as a working document in 2022)
- Drafting of reflection paper will start in 2023
- EMA and public consultations in 2024
- Possible basis for further actions and guidance
 - 14 Priya Bahri: EU-GVP



EU-GVP







Focus



Points raised by industry stakeholders?



Thank you

and thanks to PRAC and EMA colleagues and other stakeholders

Further information

Priya Bahri, Ph.D. Lead Pharmacovigilance and Risk Management Guidance and Policy Pharmacovigilance Office priya.bahri@ema.europa.eu Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Telephone +31 (0)88 781 6000 Send us a question Go to www.ema.europa.eu/contact

Follow us on **Magende Bases**